AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32829109 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated release after both acute MICT and HIIT exercise sessions
Number of subjects: 22
Study 35347875 — intervention group
Group type: EXPERIMENTAL
Intervention: Champ4Life’s intervention (n=49)
Number of subjects: 94
Study 35347875 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 94
Study 33097408 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) as a continuous variable
Number of subjects: 652
Study 33097408 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) in the second tertile
Number of subjects: 652
Study 33097408 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) in the third tertile
Number of subjects: 652
Study 32725107 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous anticoagulation with apixaban
Number of subjects: 678
Study 32725107 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 678
Study 35366354 — intervention group
Group type: EXPERIMENTAL
Intervention: +0.50 DS blur
Number of subjects: 30
Study 35366354 — intervention group
Group type: EXPERIMENTAL
Intervention: +0.75 DS blur
Number of subjects: 30
Study 35366354 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.00 DS blur
Number of subjects: 30
Study 35366354 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.25 DS blur
Number of subjects: 30
Study 35366354 — intervention group
Group type: COMPARATOR
Intervention: No Blur
Number of subjects: 30
Study 35366354 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.25 DS blur (yellow signals)
Number of subjects: 30
Study 32811741 — intervention group
Group type: EXPERIMENTAL
Intervention: Johrei treatment
Number of subjects: 0
Study 34825739 — intervention group
Group type: EXPERIMENTAL
Intervention: PainReApp mHealth system with a physical activity program
Number of subjects: 100
Study 34825739 — intervention group
Group type: COMPARATOR
Intervention: Program information in paper format (control group)
Number of subjects: 100
Study 34388360 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501 (40 mg/0.8 mL formulation)
Number of subjects: 147
Study 34388360 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab reference product (40 mg/0.4 mL or 40 mg/0.8 mL)
Number of subjects: 147
Study 34388360 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501
Number of subjects: 147
Study 34388360 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab reference product
Number of subjects: 147
Study 35244757 — intervention group
Group type: EXPERIMENTAL
Intervention: multi‐component self‐regulation intervention
Number of subjects: 151
Study 35244757 — intervention group
Group type: COMPARATOR
Intervention: information‐only control
Number of subjects: 151
Study 33157008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic genomic sequencing
Number of subjects: 117
Study 33157008 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up on genomic results
Number of subjects: 117
Study 33157008 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive tests/genomic diagnosis
Number of subjects: 117
Study 35338469 — intervention group
Group type: EXPERIMENTAL
Intervention: Upacicalcet 0.01 mg
Number of subjects: 32
Study 35338469 — intervention group
Group type: EXPERIMENTAL
Intervention: Upacicalcet 0.1 mg
Number of subjects: 32
Study 35338469 — intervention group
Group type: EXPERIMENTAL
Intervention: Upacicalcet 1.0 mg
Number of subjects: 32
Study 35338469 — intervention group
Group type: EXPERIMENTAL
Intervention: Upacicalcet 2.5 mg
Number of subjects: 32
Study 35338469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33877413 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-university hospital departments
Number of subjects: 172
Study 33877413 — intervention group
Group type: EXPERIMENTAL
Intervention: University hospital departments
Number of subjects: 172
Study 32707325 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclipse shoulder prosthesis
Number of subjects: 327
Study 32707325 — intervention group
Group type: COMPARATOR
Intervention: Univers II shoulder prosthesis
Number of subjects: 327
Study 34140055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 40
Study 34140055 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 40
Study 32289829 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids with bupivacaine (O + B)
Number of subjects: 17
Study 32289829 — intervention group
Group type: COMPARATOR
Intervention: Opioids without bupivacaine (O)
Number of subjects: 17
Study 35718502 — intervention group
Group type: EXPERIMENTAL
Intervention: Jingfang Granules
Number of subjects: 138
Study 35718502 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Jingfang Granules simulation agent)
Number of subjects: 138
Study 34905449 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HST) intervention provided to pregnant women
Number of subjects: 1618
Study 35908980 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on a training booklet approved by cancer specialists
Number of subjects: 80
Study 35908980 — intervention group
Group type: COMPARATOR
Intervention: Routine training (control group)
Number of subjects: 80
Study 32909190 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting progesterone luteal support (P4-LS) on day of egg retrieval (ER)
Number of subjects: 171
Study 32909190 — intervention group
Group type: COMPARATOR
Intervention: Starting progesterone luteal support (P4-LS) on day of embryo transfer (ET)
Number of subjects: 171
Study 32048918 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TDN) combined with manual therapy (MT) and exercise (Ex)
Number of subjects: 22
Study 32048918 — intervention group
Group type: COMPARATOR
Intervention: Manual therapy (MT) and exercise (Ex)
Number of subjects: 22
Study 33685703 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lactose milk replacer (HL; 17% fat; 44% lactose)
Number of subjects: 32
Study 33685703 — intervention group
Group type: COMPARATOR
Intervention: High-fat milk replacer (HF; 23% fat; 37% lactose)
Number of subjects: 32
Study 33685703 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lactose milk replacer (HL)
Number of subjects: 32
Study 33685703 — intervention group
Group type: COMPARATOR
Intervention: High-fat milk replacer (HF)
Number of subjects: 32
Study 33685703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 32
Study 34059724 — intervention group
Group type: EXPERIMENTAL
Intervention: NPKb + U50% (bio-chemical fertilizers)
Number of subjects: 10
Study 34059724 — intervention group
Group type: EXPERIMENTAL
Intervention: U (100% chemical fertilizer as urea at 53.3 kg ha‐1)
Number of subjects: 10
Study 34059724 — intervention group
Group type: EXPERIMENTAL
Intervention: Pb + U50% (biofertilizer with 50% urea)
Number of subjects: 10
Study 34059724 — intervention group
Group type: COMPARATOR
Intervention: Control (no fertilization)
Number of subjects: 10
Study 32038035 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPU bracelet (hypothermia monitoring device)
Number of subjects: 386
Study 32038035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypothermia monitoring device)
Number of subjects: 386
Study 35853998 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on proteinuria, emergency procedures, and serum creatinine (1 point each).
Number of subjects: 1254
Study 34252914 — intervention group
Group type: COMPARATOR
Intervention: Placebo-administered agent (subcutaneous, endovenous, or oral)
Number of subjects: 5672
Study 34252914 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of eptinezumab (anti-calcitonin gene-related peptide monoclonal antibody)
Number of subjects: 5672
Study 34252914 — intervention group
Group type: COMPARATOR
Intervention: Oral topiramate
Number of subjects: 5672
Study 34252914 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous monoclonal
Number of subjects: 5672
Study 34252914 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple head injections (botulinum toxin)
Number of subjects: 5672
Study 35137039 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIMAL programme
Number of subjects: 149
Study 35137039 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care
Number of subjects: 149
Study 32772491 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational diet based on the Mediterranean diet and Dietary Approaches to Stop Hypertension diet (group A)
Number of subjects: 60
Study 32772491 — intervention group
Group type: COMPARATOR
Intervention: Food exchange system-based diet (group B)
Number of subjects: 60
Study 32772491 — intervention group
Group type: COMPARATOR
Intervention: Food exchange system-based diet (group C)
Number of subjects: 60
Study 35325947 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral normal external auditory canal (EAC) skin graft
Number of subjects: 13
Study 35325947 — intervention group
Group type: COMPARATOR
Intervention: Scalp blade thick skin (Control)
Number of subjects: 13
Study 32823606 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) with DHA
Number of subjects: 0
Study 32823606 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 0
Study 35803039 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 45
Study 35803039 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 45
Study 35803039 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic Device (SGD)
Number of subjects: 45
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for delirium using the Cornell Assessment of Pediatric Delirium
Number of subjects: 181
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium-positive patients
Number of subjects: 181
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain score increase (per point)
Number of subjects: 181
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: Total opioid exposure increase (per mg/kg/d)
Number of subjects: 181
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: SBS less than 0
Number of subjects: 181
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication or sedative administered in the previous 4 hours
Number of subjects: 181
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: No progressive physical therapy or ambulation schedule
Number of subjects: 181
Study 33065733 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents not at bedside at time of data collection
Number of subjects: 181
Study 32390503 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation assuming a missing at random mechanism
Number of subjects: 0
Study 32390503 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation assuming a missing not at random mechanism
Number of subjects: 0
Study 32390503 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior distributions and shift parameters in the delta adjustment method
Number of subjects: 0
Study 35718625 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion (PIBI)
Number of subjects: 90
Study 33484852 — intervention group
Group type: EXPERIMENTAL
Intervention: Body odor of ovulating women (OV)
Number of subjects: 18
Study 33484852 — intervention group
Group type: EXPERIMENTAL
Intervention: Body odor of pregnant women (PRG)
Number of subjects: 18
Study 32936298 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 24349
Study 32936298 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulation alone
Number of subjects: 24349
Study 35871497 — intervention group
Group type: EXPERIMENTAL
Intervention: RD12014
Number of subjects: 49
Study 35871497 — intervention group
Group type: COMPARATOR
Intervention: Victoza
Number of subjects: 49
Study 35871497 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 34293738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate (FC) 1 tablet (1-g equivalent to 210 mg ferric iron) TID (3 g/day)
Number of subjects: 206
Study 34293738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate (FC) 2 tablets BID (4 g/day)
Number of subjects: 206
Study 34605026 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐OHB supplementation (30 mL or 12 g, thrice-daily for 14 days)
Number of subjects: 14
Study 34605026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 36336532 — intervention group
Group type: EXPERIMENTAL
Intervention: Injector feeding group
Number of subjects: 62
Study 36336532 — intervention group
Group type: COMPARATOR
Intervention: Bottle feeding group
Number of subjects: 62
Study 33789264 — intervention group
Group type: EXPERIMENTAL
Intervention: WoundClot hemostatic gauze
Number of subjects: 24
Study 33789264 — intervention group
Group type: COMPARATOR
Intervention: Cotton gauze
Number of subjects: 24
Study 32867735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-sparing nasal reservoir cannula (OSNRC)
Number of subjects: 16
Study 32867735 — intervention group
Group type: COMPARATOR
Intervention: Standard nasal cannula (SNC)
Number of subjects: 16
Study 36175471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) guided by intraoperative three-dimensional imaging of sacral CT and mobile C-arm fluoroscopy
Number of subjects: 52
Study 33165539 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulas with long and narrow tubing (CLNT)
Number of subjects: 166
Study 33165539 — intervention group
Group type: COMPARATOR
Intervention: Short binasal prongs and masks (SPM)
Number of subjects: 166
Study 35551683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg, q.d. for 4 weeks
Number of subjects: 0
Study 35551683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33734434 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic/genetic generalized epilepsies (IGEs)
Number of subjects: 402
Study 33734434 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile myoclonic epilepsy (JME)
Number of subjects: 402
Study 33734434 — intervention group
Group type: COMPARATOR
Intervention: Seizure-free patients with IGE
Number of subjects: 402
Study 33734434 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with persistent seizures
Number of subjects: 402
Study 33734434 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy with generalized tonic‐clonic seizures alone (EGTCS) and juvenile absence epilepsy (JAE)
Number of subjects: 402
Study 36255254 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Dapivirine gel administered rectally using an applicator (2.5 g)
Number of subjects: 16
Study 36255254 — intervention group
Group type: COMPARATOR
Intervention: Dapivirine gel self-administered as lubricant (up to 10 g)
Number of subjects: 16
Study 33431374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity with or without dietary advice)
Number of subjects: 208
Study 33431374 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 208
Study 36361215 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative cognitive function improvement program administered to CN and MCI groups for six weeks.
Number of subjects: 52
Study 34180278 — intervention group
Group type: EXPERIMENTAL
Intervention: CTFA-GRT (group reminiscence therapy based on Chinese traditional festival activities)
Number of subjects: 64
Study 34918965 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Directed Fluid Therapy (GDFT)
Number of subjects: 124
Study 34918965 — intervention group
Group type: COMPARATOR
Intervention: Restrictive Fluid Therapy (Control)
Number of subjects: 124
Study 34918965 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GDFT and Restrictive Fluid Therapy
Number of subjects: 124
Study 33280539 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 1: Challenged stereotypes about older adults
Number of subjects: 845
Study 33280539 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2: Challenged stereotypes about careers working with older adults
Number of subjects: 845
Study 33280539 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 3: Challenged both stereotypes
Number of subjects: 845
Study 33280539 — intervention group
Group type: COMPARATOR
Intervention: Control (Condition 4: Described careers in general)
Number of subjects: 845
Study 33280539 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions (Study 2)
Number of subjects: 845
Study 33280539 — intervention group
Group type: COMPARATOR
Intervention: Control (Study 2)
Number of subjects: 845
Study 32268439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive administration of ibuprofen or paracetamol
Number of subjects: 48
Study 32268439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32268439 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative behaviour during anaesthesia
Number of subjects: 48
Study 33074393 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy (HILT) + exercise therapy (ET)
Number of subjects: 40
Study 33074393 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser (PL) + exercise therapy (ET)
Number of subjects: 40
Study 35322719 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies that questioned existing practices
Number of subjects: 98
Study 35322719 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies that tested the practice in a randomized trial or encouraged future randomized testing
Number of subjects: 98
Study 35322719 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroenterology
Number of subjects: 98
Study 35322719 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetrics/Gynecology
Number of subjects: 98
Study 35322719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular
Number of subjects: 98
Study 32187789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education plus cognition-targeted motor control training
Number of subjects: 64
Study 32187789 — intervention group
Group type: COMPARATOR
Intervention: biomedically focused education and exercise therapy
Number of subjects: 64
Study 35359035 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% mangosteen gel
Number of subjects: 25
Study 35359035 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 25
Study 34538090 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum SBP (per 10 mm Hg increments)
Number of subjects: 1161
Study 34538090 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum SBP lower than 124 mm Hg
Number of subjects: 1161
Study 34538090 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum SBP higher than 124 mm Hg
Number of subjects: 1161
Study 34538090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean SBP
Number of subjects: 1161
Study 34264128 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 1 (280 kcal)
Number of subjects: 20
Study 34264128 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal 2 (560 kcal)
Number of subjects: 20
Study 34264128 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals 1, 2, and 3
Number of subjects: 20
Study 34264128 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in harmonic spectrum or heart rate
Number of subjects: 20
Study 35102171 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMiRNA-AR68 (AR68) at a low dose of 0.5 mg/ml applied three times per week for 24 weeks
Number of subjects: 547
Study 35102171 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMiRNA-AR68 (AR68) at a high dose of 5 mg/ml given once per week for 24 weeks
Number of subjects: 547
Study 35102171 — intervention group
Group type: COMPARATOR
Intervention: Finasteride (control)
Number of subjects: 547
Study 33737199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (SL-BUP)
Number of subjects: 2000
Study 33737199 — intervention group
Group type: COMPARATOR
Intervention: 7-day extended-release injectable buprenorphine (CAM2038, XR-BUP)
Number of subjects: 2000
Study 33908636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously every 4 weeks (continuously treated)
Number of subjects: 1753
Study 33908636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg intravenously every 4 weeks (re-treated after treatment interruption)
Number of subjects: 1753
Study 33908636 — intervention group
Group type: COMPARATOR
Intervention: Placebo maintenance (during treatment interruption)
Number of subjects: 1753
Study 35585620 — intervention group
Group type: EXPERIMENTAL
Intervention: Good home massage compliance (practiced for at least 15 minutes for three or more days in a week)
Number of subjects: 212
Study 35585620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum massage application (above median level)
Number of subjects: 212
Study 35585620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum massage application (below median level)
Number of subjects: 212
Study 35585620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum massage application (median 21.1%)
Number of subjects: 212
Study 34171279 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 309
Study 34171279 — intervention group
Group type: COMPARATOR
Intervention: 7+3 (cytarabine and daunorubicin chemotherapy)
Number of subjects: 309
Study 32577871 — intervention group
Group type: EXPERIMENTAL
Intervention: EMR with the application of 0.3 ml of N-butyl-2-cyanoacrylate + methacryloxysulfolane—Glubran 2®
Number of subjects: 30
Study 32577871 — intervention group
Group type: COMPARATOR
Intervention: EMR
Number of subjects: 30
Study 35506381 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 190
Study 35506381 — intervention group
Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 190
Study 32367748 — intervention group
Group type: EXPERIMENTAL
Intervention: Baihe Gujin decoction combined with anti-tuberculosis therapy
Number of subjects: 100
Study 32367748 — intervention group
Group type: COMPARATOR
Intervention: Anti-tuberculosis treatment
Number of subjects: 100
Study 34289275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 351
Study 34289275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351